Atomwise's JV spree

How Atomwise’s partners are thinking about deal structure for AI-driven chemistry

By Karen Tkach Tuzman, Associate Editor | Sep 19, 2019 | 10:20 PM GMT

Drug developers signing up to partner with Atomwise for hit discovery and lead optimization said deal structures made it attractive to take the plunge on the AI company's emerging technology.

Last week, Atomwise Inc. announced three JVs with U.S.-based cancer companies and a collaboration with Chinese pharma Hansoh Pharmaceutical Group Co. Ltd. (HKEX:03692). In the last year, Atomwise has also announced

Read the full 605 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE